血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)重組蛋白
Recombinant Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)
Flt1; Fms-Related Tyrosine Kinase 1; Vascular Permeability Factor Receptor; Fms-like tyrosine kinase 1; Tyrosine-protein kinase receptor FLT
- 編號(hào)RPB818Po01
- 物種Sus scrofa; Porcine (Pig，豬)相同的名稱(chēng)，不同的物種。
- 來(lái)源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
- 亞細(xì)胞定位分泌
- 預(yù)測(cè)分子量58.9kDa
- 實(shí)際分子量59kDa(差異分析請(qǐng)參閱說(shuō)明書(shū))
- 片段與標(biāo)簽Pro167~Ala424 with N-terminal His and GST Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 97%
- 等電點(diǎn)8.8
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請(qǐng)參見(jiàn)活性蛋白。 - 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格10μg50μg200μg1mg5mg
- 價(jià)格¥ 1104¥ 2760¥ 5520¥ 16560¥ 41400
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Figure. SDS-PAGE
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月，-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Sus scrofa; Porcine (Pig，豬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB818Po01 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB818Po02 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB818Po02 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)多克隆抗體 | WB; IHC; ICC; IP. |
| PAB818Po01 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB818Po81 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| LAB818Po71 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAB818Po73 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAB818Po72 | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEB818Po | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB818Po | 血管內(nèi)皮生長(zhǎng)因子受體1(VEGFR1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Clinical cardiology | Growth Differentiation Factor 15 and Coronary Collateral Formation[PubMed: 20014173] |
| Microvascular Research | Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle [PubMed: 20937289] |
| Science Alert | Antiangiogenic Activities of Cinnamon, Black and Green Tea Extracts on Experimentally Induced Breast Cancer in Rats[Scialert: Source] |
| Acta Biomater | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study[PubMed: 26689470] |
| Naunyn Schmiedebergs Arch Pharmacol | The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis[PubMed: 26269412] |
| Acta Biomaterialia | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study[Pubmed:26689470] |
| Journal?of?Cellular?Physiology | A?Human?3D?In?Vitro?Model?to?Assess?the?Relationship?Between?Osteoporosis?and?Disseminationto?Bone?of?Breast?Cancer?Tumor?Cells.[pubmed:27925188] |
| Oncotarget | Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway.[pubmed:29262624] |
| Placenta | Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery.[pubmed:28962687] |
| Acta?Biomaterialia | Synergistic effect of Si-hydroxyapatite coating and VEGF adsorption on Ti6Al4V-ELI scaffolds for bone regeneration in an osteoporotic bone environment[Pubmed: 30445158] |
| Scientific Reports | Association between Upper-airway Surgery and Ameliorative Risk Markers of endothelial function in obstructive Sleep Apnea[Pubmed: 31882827] |
| JOURNAL OF DERMATOLOGICAL TREATMENT | Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris[Pubmed: 32043381] |
| FASEB JOURNAL | Cyclin G2 upregulation impairs migration, invasion, and network formation through RNF123/Dvl2/JNK signaling in the trophoblast cell line HTR8/SVneo, a possible?…[Pubmed: 33205477] |
| Children (Basel) | sFlt-1/PlGF Ratio in Prediction of Short-Term Neonatal Outcome of Small for Gestational Age Neonates[34438609] |
| Oxid Med Cell Longev | Reactive Oxygen Species are Essential for Placental Angiogenesis During Early Gestation[Pubmed:35693704] |